BRIEF-Aardvark Therapeutics Plans To Unblind Hero And Ole Data To Inform Path Forward Following FDA Clinical Hold

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc.

AARD

0.00

May 14 (Reuters) - Aardvark Therapeutics Inc AARD.O:

  • AARDVARK THERAPEUTICS PLANS TO UNBLIND HERO AND OLE DATA TO INFORM PATH FORWARD FOLLOWING FDA CLINICAL HOLD

  • AARDVARK THERAPEUTICS INC - FDA PLACES FULL CLINICAL HOLD ON AARDVARK'S IND FOR ARD-101

  • AARDVARK THERAPEUTICS INC - CLINICAL HOLD APPLIES TO ALL ONGOING PHASE 3 HERO AND OLE TRIALS FOR ARD-101

  • AARDVARK THERAPEUTICS INC - TO UNBLIND HERO AND OLE TRIAL DATA FOR ARD-101 FOR ASSESSMENT, DETERMINE NEXT STEPS FOR THE ARD-101 PROGRAM

Source text: ID:nGNXJdz8k

Further company coverage: AARD.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.